Sarepta Hits Fresh Hurdle As Court Revives Patent Lawsuit With Regenxbio Over Muscular Disorder Therapy
A federal appeals court has reinstated a patent lawsuit filed by Regenxbio against Sarepta Therapeutics concerning Sarepta's Duchenne muscular dystrophy (DMD) treatment, Elevidys. Regenxbio alleges that Elevidys infringes on a gene-therapy patent licensed from the University of Pennsylvania and is seeking over $900 million in damages. This legal development adds to Sarepta's recent challenges, which include regulatory scrutiny following patient deaths attributed to acute liver failure after Elevidys treatment.
Sarepta Therapeutics, Inc. $SRPT Shares Bought by Aberdeen Group plc
Aberdeen Group plc significantly increased its stake in Sarepta Therapeutics (NASDAQ:SRPT) by 59.6% in the third quarter, now owning 1,982,764 shares valued at $38.2 million. This comes amidst mixed analyst ratings, with a consensus "Hold" and an average price target of $33.84, while COO Ian Michael Estepan recently sold a portion of his holdings. Sarepta's market cap is $1.86 billion, with institutional investors owning 86.68% and insiders holding 7.60% of the company.
A Look At Sarepta Therapeutics (SRPT) Valuation After New Zealand Clears Huntington’s Disease Trial
Sarepta Therapeutics' (SRPT) shares are in focus after New Zealand approved its clinical trial for SRP-1005 for Huntington's Disease. Despite a tough year for the stock, with an 83.52% decline, the company is seen as 13.7% undervalued by analysts, who have a consensus price target of $23.96. The article suggests that this could be a reset entry point for investors, depending on how the gene therapy pipeline evolves and addresses potential safety concerns or reimbursement challenges.
A Look At Sarepta Therapeutics (SRPT) Valuation After New Zealand Clears Huntington’s Disease Trial
Sarepta Therapeutics' (SRPT) shares are in focus after New Zealand approved its clinical trial for SRP-1005 in Huntington's Disease. Despite recent share price declines, the stock is considered undervalued at $17.79 against a narrative fair value of $20.61, particularly given analyst targets ranging up to $80. The article highlights potential opportunities and risks, encouraging investors to consider its gene therapy pipeline's evolution and possible market resets.
Sarepta’s SRP-1005 Trial Approval Opens New Huntington’s Disease Opportunity
Sarepta Therapeutics received Medsafe approval in New Zealand for a first-in-human clinical trial of SRP-1005, an investigational siRNA therapeutic for Huntington's Disease. This marks Sarepta's entry into Huntington's Disease research, broadening its rare disease focus beyond Duchenne muscular dystrophy. The Phase 1 study primarily aims to assess safety and dosing, creating a new clinical catalyst for the company and showcasing its genetic medicine expertise in an area with limited treatment options.
ING Groep NV Has $4.64 Million Stock Holdings in Sarepta Therapeutics, Inc. $SRPT
ING Groep NV significantly reduced its stake in Sarepta Therapeutics by 50.8% in Q3, now owning 240,800 shares valued at $4.64 million. Despite this, institutional ownership remains high at 86.68%, with some firms increasing their positions and others initiating new ones. Sarepta Therapeutics' stock trades around $17.40, with analysts holding a consensus "Hold" rating and an average price target of $33.84, while recent insider transactions show the COO selling shares.
Has Sarepta Therapeutics (SRPT) Fallen Too Far After Its Sharp Multi‑Year Share Price Slide?
This article analyzes Sarepta Therapeutics (SRPT) after a significant multi-year share price decline, noting an 83.3% drop over 1 year and 79.8% over 5 years. Using Discounted Cash Flow (DCF) and Price/Sales (P/S) analyses, Simply Wall St suggests the stock is undervalued, with a DCF intrinsic value significantly higher than its current trading price and a P/S ratio well below industry averages. The article also introduces "Narratives" as a way for investors to develop their own valuation based on future projections.
Sarepta Therapeutics To Announce Fourth Quarter And Full-Year 2025 Financial Results
Sarepta Therapeutics (SRPT) is set to announce its financial results for the fourth quarter and full-year 2025. This news comes from Reuters and is a brief update for investors and market watchers. The announcement will cover the company's performance and financial standing for the specified periods.
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results
Sarepta Therapeutics (NASDAQ:SRPT) will release its fourth quarter and full-year 2025 financial results after the Nasdaq Global Market closes on Wednesday, Feb. 25, 2026. Following the release, the company will host a conference call at 4:30 p.m. E.T. to discuss the results, which will be webcast live on its investor relations website. Sarepta Therapeutics is a leader in precision genetic medicine for rare diseases, particularly Duchenne muscular dystrophy.
Sarepta Therapeutics to Report Q4 and Full-Year 2025 Financial Results
Sarepta Therapeutics (SRPT) is scheduled to release its Q4 and full-year 2025 financial results after the Nasdaq Global Market closes on February 25, 2026, followed by a conference call at 4:30 p.m. E.T. The company, a leader in precision genetic medicine for rare diseases like Duchenne muscular dystrophy, emphasizes transparency through a live webcast and archived replay for investors. Analysts currently project an average 1-year price target of $20.80 for SRPT, with 4 'Buy' and 10 'Hold' ratings.
New York State Common Retirement Fund Has $703,000 Position in Sarepta Therapeutics, Inc. $SRPT
The New York State Common Retirement Fund significantly reduced its stake in Sarepta Therapeutics ($SRPT) by 71.9% in Q3, now holding 36,471 shares valued at $703,000. Sarepta's COO, Ian Michael Estepan, also sold a substantial number of shares, decreasing his ownership by 6.39%. Despite institutional investors owning 86.68% of the stock, analysts have a consensus "Hold" rating with a target price of $33.84 for the company, which has a market capitalization of approximately $1.92 billion.
(SRPT) Risk Channels and Responsive Allocation
This article provides an AI-generated analysis of Sarepta Therapeutics Inc. (NASDAQ: SRPT), indicating weak sentiment across all horizons and suggesting a short bias. It highlights a significant 302.0:1 risk-reward short setup targeting 85.2% downside against 0.3% risk. The analysis details different trading strategies, including long, momentum breakout, and risk hedging (short) strategies, along with multi-timeframe signal analysis.
New Zealand OKs Phase 1 trial of Huntington’s therapy SRP-1005
New Zealand has approved Sarepta Therapeutics to begin a Phase 1 clinical trial for SRP-1005, an investigational therapy for Huntington’s disease. The trial, named INSIGHTT, will assess the safety and tolerability of the subcutaneous injection in approximately 24 participants, with an expected start between April and June. SRP-1005 is designed to halt the production of the mutated huntingtin protein by utilizing small interfering RNA (siRNA) and is intended to slow disease progression.
Global Gene Therapy and CRISPR Market Shows Billion Dollar Growth with Novartis Zolgensma 1.2 Billion Sarepta Elevidys 611 Million and Emerging CRISPR Collaborations 20 Million
The gene therapy and CRISPR market is experiencing rapid growth, driven by key players like Sarepta and Novartis generating significant revenue from therapies such as Elevidys and Zolgensma. Despite many companies remaining in clinical stages, strategic acquisitions by large firms like Eli Lilly and ongoing government support indicate a strong future for the sector. Precedence Research offers insights into market trends, revenue generation, and regulatory landscapes for informed strategic decisions.
Following Sarepta Woes, Others Look To Unlock the Next Chapter in DMD Treatment
The Duchenne muscular dystrophy (DMD) treatment landscape is seeing increased momentum with several new therapies from Avidity Biosciences, REGENXBIO, and Capricor Therapeutics nearing regulatory review. This comes as Sarepta's Elevidys faces scrutiny, potentially opening the market for competitors. CureDuchenne, an advocacy group, highlights these upcoming therapies as significant advancements for the neuromuscular disease.
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Average Rating of "Hold" by Brokerages
Sarepta Therapeutics (NASDAQ:SRPT) has received an average "Hold" rating from 28 brokerages, with an average 12-month price target of $33.84. Despite a brutal 2025 where the company missed EPS estimates and saw a revenue decline, some analysts still project significant upside. Institutional investors hold approximately 86.7% of the stock, while the COO recently sold shares, reducing insider ownership to about 7.6%.
Sarepta saga has ‘gone on too long’ as competitors catch up
Sarepta's gene therapy, Elevidys, for Duchenne muscular dystrophy has faced criticism and a significant drop in stock price due to high cost ($3.2 million), limited data provided to the community, and three deaths linked to the therapy. These issues have led to frustration among patient families and investors, underscoring concerns about patient safety and the company's communication practices. The company's share price plummeted 80% from the beginning of 2025.
Is Sarepta (SRPT) Quietly Redefining Its Rare Disease Strategy With a Huntington’s Trial Bet?
Sarepta Therapeutics (SRPT) has expanded its focus beyond Duchenne muscular dystrophy by gaining Medsafe approval in New Zealand for a Phase 1 clinical trial (INSIGHTT) of SRP-1005, an investigational siRNA therapy for Huntington’s Disease. This move represents a long-tail catalyst for Sarepta, reinforcing the value of its gene therapy and RNA platforms and its cost discipline, although it doesn't immediately alter the core risk-reward drivers. The company's investment narrative is centered on the execution of its existing therapies and regulatory clarity, with its shares currently subject to varied fair value estimates among analysts.
Sarepta Saga Has ‘Gone on Too Long’ as Competitors Catch Up
Sarepta Therapeutics is facing increasing skepticism from investors and patients following a series of deaths linked to its gene therapies, particularly Elevidys, for Duchenne muscular dystrophy (DMD). Despite defending its data, the company's stock has plummeted, and its Q4 2025 sales for Elevidys missed consensus estimates. With competitors like REGENXBIO nearing market entry and a tarnished brand, analysts question Sarepta's future viability and its ability to maintain its market position.
Sarepta Therapeutics Announces Approval of Clinical Trial Application for SRP-1005, Its Investigational Treatment for Huntington’s Disease
Sarepta Therapeutics announced that Medsafe in New Zealand has approved its Clinical Trial Application for SRP-1005 (INSIGHTT), an investigational siRNA therapeutic for Huntington's Disease. The Phase 1 study, which will evaluate the safety and tolerability of subcutaneous dosing, is expected to begin in the second quarter of 2026. SRP-1005 uses an advanced TfR1 approach for efficient delivery to the central nervous system and has shown potential for significant protein knockdown in preclinical studies.
Assessing Sarepta Therapeutics (SRPT) Valuation After Positive Three Year EMBARK Data For Elevidys
Sarepta Therapeutics (SRPT) recently announced positive three-year functional results from its Phase 3 EMBARK study for Elevidys, showing sustained motor function benefits without new safety concerns. Despite this encouraging news, the company's share price has seen significant declines over the past year and three years. An analysis suggests Sarepta's fair value is $20.61, indicating it is currently undervalued, but future performance depends on avoiding safety setbacks and managing gene therapy access issues.
Sarepta Therapeutics Announces Approval of Clinical Trial Application for SRP-1005, Its Investigational Treatment for Huntington’s Disease
Sarepta Therapeutics announced that Medsafe in New Zealand has approved its clinical trial application for SRP-1005 (formerly ARO-HTT), an investigational small interfering RNA (siRNA) therapeutic for Huntington's Disease. The first-in-human clinical study, INSIGHTT, a Phase 1 multi-center dose escalation study, is expected to begin in the second quarter of 2026 to evaluate the safety and tolerability of subcutaneous dosing of SRP-1005. This therapeutic leverages an advanced TfR1 approach designed for efficient delivery to the central nervous system via subcutaneous administration.
Assessing Sarepta Therapeutics (SRPT) Valuation After Positive Three Year EMBARK Data For Elevidys
Sarepta Therapeutics' Elevidys has shown positive three-year functional results from its Phase 3 EMBARK study, maintaining motor function benefits in Duchenne muscular dystrophy patients with no new safety concerns. Despite this encouraging clinical update, Sarepta's stock has performed poorly over the past year and three years, though short-term momentum shows signs of rebuilding. A common valuation narrative suggests SRPT is 1.6% undervalued at $20.61, highlighting the potential for future growth, but also notes risks like safety setbacks and access issues for gene therapies.
Sarepta Therapeutics, Inc. (SRPT) Stock Analysis: A Closer Look at Its 5.38% Potential Upside
Sarepta Therapeutics (SRPT) is a significant biotechnology player focused on RNA-targeted therapeutics and gene therapies for rare diseases, particularly Duchenne muscular dystrophy. Despite current losses and revenue decline, analysts project improved profitability with a modest 5.38% potential upside. The company's innovative approach and strategic partnerships present a compelling yet risky investment opportunity, dependent on regulatory milestones and therapeutic developments.
Sarepta’s Elevidys Data Reshapes Duchenne Risk Profile For Long-Term Investors
Sarepta Therapeutics reported positive three-year Phase 3 EMBARK results for Elevidys in Duchenne muscular dystrophy, showing sustained efficacy and no new safety issues, leading to an expanded FDA label. This clinical data could significantly influence how investors view Sarepta's long-term risk profile and opportunity, despite the stock's recent decline. Key factors to watch include the translation of the updated label into patient volumes, payer negotiations for the one-time therapy, and future data on non-ambulant populations.
Sarepta’s Elevidys Data Reshapes Duchenne Risk Profile For Long-Term Investors
Sarepta Therapeutics' Elevidys reported positive three-year Phase 3 EMBARK results for Duchenne muscular dystrophy, showing sustained efficacy and no new safety issues, leading to an updated FDA label. This data is critical for long-term investors, as the stock has experienced significant declines, and the findings address concerns about the gene therapy's durability and safety. The company's risk profile refocuses on the therapy's clinical effectiveness and regulatory path amidst competition.
Y Intercept Hong Kong Ltd Lowers Position in Sarepta Therapeutics, Inc. $SRPT
Y Intercept Hong Kong Ltd significantly reduced its stake in Sarepta Therapeutics (NASDAQ:SRPT) by 91% in the third quarter, selling 791,446 shares and retaining 78,735 shares valued at approximately $1.52 million. This reduction comes as Sarepta missed EPS estimates for the quarter despite exceeding revenue expectations, and its stock dipped 4.2%. Analysts currently hold a "Hold" rating for SRPT with an average target price of $33.84.
Commit To Purchase Sarepta Therapeutics At $15, Earn 22.2% Annualized Using Options
Investors looking to purchase Sarepta Therapeutics (SRPT) stock at a lower price than its current market value of $20.40 per share can consider selling a January 2027 put contract at the $15 strike price. This strategy offers a potential 22.2% annualized rate of return, known as "YieldBoost," by collecting a premium of $3.20. While it limits upside potential compared to owning shares directly, it presents an opportunity to acquire the stock at a lower cost basis if the contract is exercised.
How Sarepta’s Long-Term ELEVIDYS Duchenne Data At Sarepta Therapeutics (SRPT) Has Changed Its Investment Story
Sarepta Therapeutics' recent three-year topline results from its EMBARK trial for ELEVIDYS show statistically significant and durable improvements in motor function for Duchenne muscular dystrophy patients, reinforcing the treatment's long-term benefits. This data strengthens the investment narrative around ELEVIDYS's durability and safety, addressing physician confidence and payer discussions. Despite these positive results, the company still faces market uncertainties, including execution risk and regulatory setbacks, leading to a wide range of fair value estimates for SRPT stock.
How Sarepta’s Long-Term ELEVIDYS Duchenne Data At Sarepta Therapeutics (SRPT) Has Changed Its Investment Story
Sarepta Therapeutics' recent three-year data from its Phase 3 EMBARK trial for ELEVIDYS has significantly improved its investment narrative by demonstrating durable motor function improvements and no new safety signals in Duchenne muscular dystrophy patients. This long-term efficacy enhances confidence for physicians and payers, supporting broader global uptake. However, uncertainties persist due to the FDA's boxed warning, the loss of a non-ambulant indication, and market skepticism reflected in the stock's current valuation, indicating that execution risk is still heavily discounted.
Sarepta Therapeutics Elevidys Data Highlights Durable Duchenne Benefits And Risks
Sarepta Therapeutics reported positive 3-year data for its Elevidys gene therapy, showing sustained functional benefits and a manageable safety profile in ambulatory Duchenne muscular dystrophy patients. This data addresses previous concerns regarding long-term efficacy and safety, reinforcing Elevidys's position as a core asset for Sarepta. While the therapy still carries a strong FDA safety warning, the results are expected to influence regulatory, physician, caregiver, and payer perceptions of Duchenne gene therapy.
SRPT Stock Up 8% on Positive Long-Long-Term Data From Elevidys Study in DMD
Sarepta Therapeutics (SRPT) shares rose nearly 8% after announcing positive three-year data from Part 1 of its phase III EMBARK study for Elevidys in ambulatory Duchenne muscular dystrophy (DMD) patients. The study showed Elevidys slowed disease progression and maintained or improved motor function, with no new safety signals. Despite this positive news boosting the stock, the company's Elevidys sales in Q3 2025 were lower than Q3 2024 due to previous safety concerns and label updates that restricted its use to ambulatory patients.
HC Wainwright Reiterates Sell Rating for Sarepta Therapeutics (NASDAQ:SRPT)
HC Wainwright has reiterated a "Sell" rating for Sarepta Therapeutics (NASDAQ:SRPT), despite mixed analyst coverage and an average "Hold" rating with a target price of $33.84. Sarepta recently missed EPS estimates but exceeded revenue expectations, though its stock currently trades around $22.80 with a market cap of $2.39 billion. While positive three-year EMBARK study results for ELEVIDYS have sparked optimism, concerns persist regarding prior patient fatalities, FDA restrictions, and potential regulatory and labeling risks, as highlighted by other analysts.
Sarepta Therapeutics Elevidys Data Highlights Durable Duchenne Benefits And Risks
Sarepta Therapeutics reported positive 3-year data from its EMBARK Phase 3 study for Elevidys gene therapy in Duchenne muscular dystrophy, showing sustained functional benefits in ambulatory patients and a manageable safety profile with no new issues. This update addresses previous concerns around long-term efficacy and safety, reinforcing Elevidys's potential as a core asset for Sarepta despite existing regulatory warnings and the company's broader financial risks. The data's impact on regulatory, clinical, and payer adoption, especially for non-ambulatory patients and in other regions, will be key to watch.
Sarepta Stock Climbs. 3-Year Study Results for Elevidys Bring Hope.
Sarepta Therapeutics' stock rose following the announcement of positive top-line results from a three-year study evaluating its Duchenne muscular dystrophy gene therapy, Elevidys. The study's findings bring renewed hope regarding the efficacy of the treatment for patients with the condition.
Baird raises Sarepta Therapeutics stock price target to $22 on positive data
Baird has increased its price target for Sarepta Therapeutics (NASDAQ:SRPT) to $22.00 from $15.00, while maintaining a Neutral rating. This adjustment follows encouraging three-year data from Sarepta’s EMBARK study for its Elevidys treatment, showing durable efficacy and no new safety concerns. RBC Capital, however, maintains a Sector Perform rating due to concerns about slowing growth in Duchenne treatments.
Sarepta Therapeutics shares rise on positive Duchenne gene therapy data
Sarepta Therapeutics (NASDAQ:SRPT) shares increased after the company reported positive three-year results from its Phase 3 EMBARK study for ELEVIDYS, a gene therapy for ambulatory Duchenne muscular dystrophy patients. The study showed statistically significant slowing of disease progression, with patients maintaining or improving functional scores compared to an untreated control group. Analysts at Jefferies reiterated a 'Buy' rating and a $30 price target, anticipating increased real-world demand and other potential stock drivers in 2026.
Sarepta’s DMD Gene Therapy Staves Off Disease Three Years After Treatment
Sarepta announced positive year three data from its Phase III EMBARK trial for Elevidys, a gene therapy for Duchenne muscular dystrophy. The data showed significant improvements in motor function and a slowing of disease progression in treated patients, leading to a 9% rise in Sarepta's shares. This positive news follows a challenging 2025 where patient deaths linked to liver injury resulted in regulatory difficulties, a workforce reduction, and a black box warning for the therapy.
Sarepta's Duchenne gene therapy slows disease progression at three years
Sarepta Therapeutics announced that its gene therapy, Elevidys, for Duchenne muscular dystrophy, significantly slowed disease progression and maintained patients' motor function three years post-treatment. The long-term data, which showed up to a 73% reduction in the rate of functional decline compared to an untreated control group, caused Sarepta's shares to rise over 12%. Despite previous scrutiny and safety warnings concerning liver injury, analysts believe this new data could improve perception and accelerate commercial adoption of the therapy for ambulatory patients aged four and older.
Sarepta Announces Positive Topline Three-Year EMBARK Results Showing ELEVIDYS Significantly Slows Disease Progression on Key Functional Measures in Ambulatory Duchenne Patients
Sarepta Therapeutics announced positive three-year topline results from its EMBARK study, demonstrating that ELEVIDYS significantly slows disease progression in ambulatory Duchenne muscular dystrophy patients. The gene therapy showed sustained and increasing efficacy across key motor function measures like NSAA, Time to Rise, and 10-meter walk/run, with a 70% or greater reduction in the rate of decline compared to an external control group. The study also reinforced ELEVIDYS's manageable safety profile, with no new treatment-related safety signals observed.
Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Up 13.9% on Analyst Upgrade
Sarepta Therapeutics (NASDAQ:SRPT) saw its stock price rise by 13.9% in mid-day trading after Wedbush upgraded its price target from $32 to $34 while maintaining an outperform rating. Despite missing EPS estimates but beating revenue in the latest quarter, institutional investors own a significant portion of the stock. Analysts currently hold a consensus "Hold" rating with an average target price of $33.84, reflecting mixed opinions among 9 Buy, 13 Hold, and 6 Sell ratings.
A Look At Sarepta Therapeutics (SRPT) Valuation As EMBARK Phase 3 ELEVIDYS Readout Nears
Sarepta Therapeutics (SRPT) is nearing a key readout for its EMBARK Phase 3 ELEVIDYS trial, prompting renewed investor focus. Analysts are split on its valuation, with a consensus price target of $23.96 but significant divergence between bullish and bearish views. Despite a recent share price decline, the company's discounted cash flow model suggests a significant undervaluation at its current price.
Sarepta Therapeutics (SRPT) to Release 3-Year EMBARK Study Results on Elevidys, Stock Up 10%
Sarepta Therapeutics (SRPT) will release three-year results from its EMBARK study on Elevidys for Duchenne muscular dystrophy patients on January 26, prompting a 10% stock jump in after-hours trading. Despite previous preliminary findings not meeting market expectations, investors are keenly awaiting the new data, which will be discussed in a webcast. Analysts currently forecast a fall in SRPT stock price over the next 12 months, with an average target of $20.80.
Sarepta Therapeutics to Report 3-Year Topline Data from EMBARK Study of ELEVIDYS Gene Therapy in Ambulatory Individuals with Duchenne Muscular Dystrophy
Sarepta Therapeutics announced it will host a webcast and conference call on Monday, January 26, 2026, at 8:30 am ET to present 3-year topline functional results from Part 1 of the EMBARK study. This study evaluates ELEVIDYS gene therapy in ambulatory individuals aged four to seven with Duchenne muscular dystrophy. The company emphasizes its mission to develop precision genetic medicines for rare diseases and encourages investors to consult its website for important information.
Sarepta to present 3-year ELEVIDYS data for Duchenne on Jan. 26
Sarepta Therapeutics (NASDAQ: SRPT) will present 3-year functional results from its EMBARK study of ELEVIDYS, its gene therapy for Duchenne muscular dystrophy, on January 26, 2026. The company has seen significant price recovery despite a challenging year, with ELEVIDYS contributing substantially to its 2025 net product revenue. Analyst opinions on Sarepta are mixed, with some reiterating sell ratings while others maintain outperform ratings, reflecting ongoing challenges and optimism for the company's financial and research endeavors.
Sarepta to present 3-year ELEVIDYS gene therapy data on Jan. 26
Sarepta Therapeutics (NASDAQ: SRPT) is set to present 3-year results from its EMBARK study of ELEVIDYS gene therapy on January 26, 2026. The company will host a webcast and conference call to discuss topline functional results from patients treated in Part 1 of the global, randomized placebo-controlled Phase 3 study. ELEVIDYS is a gene therapy for ambulatory individuals aged four to seven with Duchenne muscular dystrophy.
Sarepta Therapeutics to Report 3-Year Topline Data from EMBARK Study of ELEVIDYS Gene Therapy in Ambulatory Individuals with Duchenne Muscular Dystrophy
Sarepta Therapeutics announced it will host a webcast and conference call on Monday, January 26, 2026, at 8:30 am EST to present 3-year topline functional results from Part 1 of the EMBARK study. This Phase 3 study evaluates ELEVIDYS gene therapy in ambulatory individuals aged four to seven with Duchenne muscular dystrophy. The company is a leader in precision genetic medicine for rare diseases.
Wedbush Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Raises Target Price to $34
Wedbush analyst Yun Zhong has reiterated a Buy rating on Sarepta Therapeutics (SRPT.US) and increased the target price from $32 to $34. According to TipRanks data, the analyst has a 43.6% success rate and a -3.8% average return over the past year. This report summarizes the analyst's updated recommendation and provides context on TipRanks' methodology for evaluating analyst performance.
Sarepta Therapeutics and Teladoc Health Face Major Challenges, 2026 Outlook Dismal
Sarepta Therapeutics and Teladoc Health are currently facing significant challenges that could lead to a dismal outlook for 2026. Sarepta's stock has plunged due to safety concerns with its Elevidys treatment, leading to an uncertain revenue outlook. Teladoc Health is experiencing shrinking market share and ongoing net losses, with international expansion facing similar competitive pressures.
2 Beaten-Down Stocks That Could Sink Even More in 2026
This article discusses why Sarepta Therapeutics (SRPT) and Teladoc Health (TDOC), despite being beaten down, could continue to underperform in 2026. Sarepta faces safety concerns with its gene therapy Elevidys, leading to decreased demand and a cautious outlook. Teladoc struggles with increased competition and declining performance in its BetterHelp platform, making both stocks unattractive investments.
